Patents by Inventor Stephane Leclair

Stephane Leclair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTIC LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES COMPRISING THEM
    Publication number: 20250034269
    Abstract: The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 18, 2024
    Publication date: January 30, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberta Bianchi, Felix Bormann, Michelle Victoria Brydon, Stefan Dengl, Harald Duerr, Guy Georges, Lydia Jasmin Hanisch, Monika Heidrich, Ralf Hosse, Leo Frederik Kunz, Stephane Leclair, Desirée Leisibach, Fanny Mende, Olaf Mundigl, Miroslav Nikolov, Pablo Umaña, Cornelia Wagner
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20240417455
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 19, 2024
    Applicant: MORPHOSYS AG
    Inventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
  • Bispecific antigen binding molecules capable of specific binding to CD40 and to fap
    Patent number: 12145994
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: November 19, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Alexander Bujotzek, Harald Duerr, Guy Georges, Christian Klein, Stephane Leclair, Moritz Rapp, Eva Carina Sum, Christine Trumpfheller, Pablo Umaña
  • IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
    Publication number: 20240043535
    Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
  • NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
    Publication number: 20210188992
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 24, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20210130451
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: MORPHOSYS AG
    Inventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
  • Treatment for rheumatoid arthritis
    Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
    Publication number: 20180340030
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 29, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20180230208
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 16, 2018
    Applicant: Morphosys Ag
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20150246969
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: September 19, 2013
    Publication date: September 3, 2015
    Applicant: MORPHOSYS AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl